Overview

Efficacy and Safety of Zuberitamab Combined with Bendamustine, Followed by Monotherapy Maintenance, in Treatment-nave Follicular Lymphoma

Status:
NOT_YET_RECRUITING

Trial end date:
2034-02-01

Target enrollment:

Participant gender:

Summary

This is a prospective, single-arm, multicenter, phase ll clinical trial to evaluate the efficacy and safety of Zuberitamab and Bendamustine combination treatment in treatment-nave follicular lymphoma patients.

Phase:

PHASE2

Details

Lead Sponsor:

Sun Yat-sen University

Collaborators:

Fifth Affiliated Hospital of Guangzhou Medical University
Fifth Affiliated Hospital, Sun Yat-Sen University
Gansu Cancer Hospital
Ganzhou Cancer Hospital

Treatments:

Bendamustine Hydrochloride